Aperio Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $103M | Sell |
1,664,612
-28,447
| -2% | -$1.75M | 0.31% | 56 |
|
|
2020
Q3 | $102M | Buy |
1,693,059
+95,680
| +6% | +$5.76M | 0.34% | 51 |
|
|
2020
Q2 | $93.9M | Buy |
1,597,379
+17,518
| +1% | +$1.05M | 0.35% | 50 |
|
|
2020
Q1 | $88.1M | Sell |
1,579,861
-8,301
| -0.5% | -$507K | 0.39% | 47 |
|
|
2019
Q4 | $102M | Buy |
1,588,162
+651,003
| +69% | +$37.3M | 0.37% | 47 |
|
|
2019
Q3 | $47.5M | Buy |
937,159
+157,369
| +20% | +$7.4M | 0.19% | 109 |
|
|
2019
Q2 | $35.4M | Sell |
779,790
-45,057
| -5% | -$2.1M | 0.14% | 153 |
|
|
2019
Q1 | $39.4M | Sell |
824,847
-33,238
| -4% | -$1.66M | 0.17% | 128 |
|
|
2018
Q4 | $44.6M | Sell |
858,085
-70,319
| -8% | -$3.78M | 0.22% | 93 |
|
|
2018
Q3 | $57.6M | Buy |
928,404
+83,708
| +10% | +$4.97M | 0.25% | 79 |
|
|
2018
Q2 | $46.7M | Sell |
844,696
-117,883
| -12% | -$6.37M | 0.22% | 92 |
|
|
2018
Q1 | $60.9M | Buy |
962,579
+51,667
| +6% | +$3.32M | 0.3% | 67 |
|
|
2017
Q4 | $55.8M | Buy |
910,912
+56,455
| +7% | +$3.53M | 0.28% | 65 |
|
|
2017
Q3 | $54.5M | Buy |
854,457
+96,561
| +13% | +$5.64M | 0.31% | 62 |
|
|
2017
Q2 | $42.2M | Buy |
757,896
+42,746
| +6% | +$2.33M | 0.26% | 80 |
|
|
2017
Q1 | $38.9M | Sell |
715,150
-47,512
| -6% | -$2.61M | 0.27% | 77 |
|
|
2016
Q4 | $44.6M | Buy |
762,662
+132,197
| +21% | +$7.23M | 0.34% | 54 |
|
|
2016
Q3 | $34M | Sell |
630,465
-132,261
| -17% | -$8.5M | 0.25% | 88 |
|
|
2016
Q2 | $56.1M | Buy |
762,726
+66,553
| +10% | +$4.7M | 0.44% | 44 |
|
|
2016
Q1 | $44.5M | Buy |
696,173
+35,593
| +5% | +$2.24M | 0.38% | 49 |
|
|
2015
Q4 | $45.4M | Buy |
660,580
+76,381
| +13% | +$5.05M | 0.42% | 47 |
|
|
2015
Q3 | $34.6M | Buy |
584,199
+32,774
| +6% | +$2.08M | 0.35% | 54 |
|
|
2015
Q2 | $36.7M | Buy |
551,425
+47,399
| +9% | +$3.12M | 0.38% | 49 |
|
|
2015
Q1 | $32.5M | Buy |
504,026
+43,606
| +9% | +$2.73M | 0.36% | 51 |
|
|
2014
Q4 | $27.2M | Buy |
460,420
+36,340
| +9% | +$2.05M | 0.34% | 57 |
|
|
2014
Q3 | $21.7M | Buy |
424,080
+43,908
| +12% | +$2.19M | 0.29% | 70 |
|
|
2014
Q2 | $18.4M | Sell |
380,172
-18,810
| -5% | -$927K | 0.27% | 79 |
|
|
2014
Q1 | $20.7M | Buy |
+398,982
| New | +$21.2M | 0.29% | 59 |
|
|
2013
Q4 | – | Sell |
-322,393
| Closed | -$16.4M | – | 56 |
|
|
2013
Q3 | $14.9M | Buy |
322,393
+23,959
| +8% | +$1.05M | 0.29% | 60 |
|
|
2013
Q2 | $13.3M | Buy |
+298,434
| New | +$13M | 0.32% | 53 |
|
Other funds holding BMY
Aperio Group's BMY Position: Q4 2020 in Review
Aperio Group reduced its Bristol-Myers Squibb (BMY) stake by 1.7% in Q4 2020, selling an estimated $1.75M and leaving 1,664,612 shares worth $103M. The position accounts for 0.31% of the portfolio, ranked #56.
Aperio Group first reported a position in BMY in Q2 2013 and has held it in 30 quarters since. 2,360 funds tracked by Wall St. Rank hold BMY as of Q4 2020.
- Aperio Group held 1,664,612 shares of Bristol-Myers Squibb worth $103M as of Q4 2020.
- Aperio Group sold 28,447 Bristol-Myers Squibb shares in Q4 2020, an estimated $1.75M.
- Bristol-Myers Squibb made up 0.31% of Aperio Group's portfolio in Q4 2020, its #56 holding.
- Aperio Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 30 quarters since.
- 2,360 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.